Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

468
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
468
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

505
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
505
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

507
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
507
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

674
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
674
Survival Tree01:19

Survival Tree

342
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
342
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

206
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Golgi casein kinase-mediated phosphorylation of osteopontin orchestrates macrophage- lung-resident mesenchymal stem cells crosstalk and fibrogenesis: a targetable macromolecular axis.

International journal of biological macromolecules·2026
Same author

Ultrafast Hopping Transfer Enables High-Anion Conduction.

Journal of the American Chemical Society·2026
Same author

AL109933.1 inhibits hepatocellular carcinoma progression via downregulating the Warburg effect and inactivating the YY1/PKM2/PIK3R1/PI3K/AKT/ mTOR/HIF-1α axis.

Cellular signalling·2026
Same author

Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: an Evaluation of the COVID-19 Pandemic.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.

Journal of translational medicine·2026

Related Experiment Video

Updated: Dec 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

Constructing dynamic treatment regimes with shared parameters for censored data.

Ying-Qi Zhao1, Ruoqing Zhu2, Guanhua Chen3

  • 1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Statistics in Medicine
|January 18, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces censored shared-Q-learning and censored shared-O-learning for developing consistent dynamic treatment regimes. These methods effectively estimate shared parameters for adaptive medical decision-making, even with censored survival data.

Keywords:
O-learningQ-learningcensored datadynamic treatment regimesshared parameters

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Related Experiment Videos

Last Updated: Dec 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Area of Science:

  • Biostatistics
  • Clinical Epidemiology
  • Machine Learning

Background:

  • Dynamic treatment regimes adapt medical decisions to evolving patient characteristics.
  • Maintaining consistent decision rule formats over time is clinically desirable.
  • Estimating shared parameters for consistent rules with censored survival data is challenging.

Purpose of the Study:

  • To develop novel methods for estimating dynamic treatment regimes with shared parameters.
  • To address challenges posed by censored survival outcomes in rule derivation.
  • To incorporate clinical preferences into qualitative, consistent decision rules.

Main Methods:

  • Proposed censored shared-Q-learning and censored shared-O-learning methods.
  • Simultaneous estimation of shared parameters across decision points.
  • Application to survival time data with censoring.

Main Results:

  • Simulation studies demonstrated superior performance of the proposed methods.
  • The methods successfully derived treatment rules for cardiovascular disease.
  • Validated the effectiveness of censored shared-Q-learning and censored shared-O-learning.

Conclusions:

  • Censored shared-Q-learning and censored shared-O-learning provide robust frameworks for adaptive treatment strategies.
  • These methods facilitate the development of consistent, personalized medical decision rules.
  • The approach is applicable to complex clinical data, including the Framingham Heart Study.